NCT02769507

Brief Summary

The present study aims to investigate whether transcranial direct current stimulation (tDCS) reduces auditory hallucinations in patients with psychosis. In addition, the neuronal changes of tDCS will be examined.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 6, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 11, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

July 1, 2016

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2020

Completed
Last Updated

August 7, 2020

Status Verified

August 1, 2020

Enrollment Period

3.7 years

First QC Date

May 6, 2016

Last Update Submit

August 6, 2020

Conditions

Outcome Measures

Primary Outcomes (5)

  • Auditory Hallucination Rating Scale (AHRS)

    Measure for severity of hallucinations

    Change from Baseline to immediately after treatment and 3 months after treatment

  • Questionnaire for Psychotic Experiences (QPE)

    Measure for severity of hallucinations

    Change from Baseline to immediately after treatment and 3 months after treatment

  • Positive and Negative Syndrome Scale (PANSS)

    Measure for positive and negative symptoms in psychotic disorders

    Change from Baseline to immediately after treatment and 3 months after treatment

  • Hallucinations App

    iPhone/iPod application for self-ratings of auditory hallucinations

    Continuously between baseline and 3 months after treatment

  • Hallucination Change Scale (HCS)

    Measure for changes in severity of auditory hallucinations

    Change from Baseline to immediately after treatment and 3 months after treatment

Secondary Outcomes (13)

  • Stroop task

    Change from Baseline to immediately after treatment and 3 months after treatment

  • Trailmaking test A and B

    Change from Baseline to immediately after treatment and 3 months after treatment

  • Expectations Questionnaire

    Change from Baseline to immediately after treatment and 3 months after treatment

  • Adverse Effects Questionnaire

    The questionnaire is completed after each tDCS session. That is, twice on each day of the five day treatment program

  • The Clinical Global Impressions Scale - Severity

    Change from Baseline to immediately after treatment and 3 months after treatment

  • +8 more secondary outcomes

Study Arms (2)

real tDCS

EXPERIMENTAL

DC Stimulator PLUS (NeuroConn) The real tDCS condition comprises two daily sessions of 20 min tDCS, separated by a minimum break of 3h, for five consecutive days. Anodal and cathodal tDCS will be applied with 2mA to the left dorsolateral prefrontal cortex (a point midway between F3 and FP1) and the left peri-Sylvian region (a point midway between T3 and P3), respectively. Electrode size is 7cm x 5cm.

Device: DC Stimulator PLUS (NeuroConn)

sham tDCS

SHAM COMPARATOR

DC Stimulator PLUS (NeuroConn) The sham condition is identical to the "real tDCS" condition except that after 40s of tDCS stimulation is going to be reduced to a small pulse every 550msec (110 μA over 15 msec) through the remainder of the 20 minute period.

Device: DC Stimulator PLUS (NeuroConn)

Interventions

real tDCSsham tDCS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with schizophrenia spectrum disorder or other psychotic disorder
  • Frequent auditory hallucinations (at least 5 times a week).
  • Patients are on a stable dose of antipsychotic medication (which can also be zero) for at least 2 weeks.
  • Mentally competent for informed consent.
  • Provided informed consent.

You may not qualify if:

  • Metal objects in or around the head that cannot be removed (i.e. cochlear implant, surgical clips, piercing)
  • History of seizures, or a history of seizures in first-degree relatives.
  • History of eye trauma with a metal object or professional metal workers
  • History of brain surgery, brain infarction, head trauma, cerebrovascular accident, broken skull, brain tumour, heart disease, cardiac pacemaker.
  • Skin disease on the scalp on the position of the tDCS electrodes
  • Coercive treatment based on a judicial ruling
  • Pregnancy in female patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Bergen

Bergen, Hordaland, 5009, Norway

Location

MeSH Terms

Conditions

Psychotic Disorders

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Marco Hirnstein, PhD

    University of Bergen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

May 6, 2016

First Posted

May 11, 2016

Study Start

July 1, 2016

Primary Completion

March 1, 2020

Study Completion

March 1, 2020

Last Updated

August 7, 2020

Record last verified: 2020-08

Data Sharing

IPD Sharing
Will share

Data will be shared with the ERC Advanced Projects Advanced Grant #249516 "VOICE" and #693124 "ONOFF".

Locations